These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12044289)

  • 1. Antifungal drug resistance: does it matter?
    Rogers TR
    Int J Infect Dis; 2002 Mar; 6 Suppl 1():S47-53. PubMed ID: 12044289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal susceptibility testing. New technology and clinical applications.
    Pfaller MA; Yu WL
    Infect Dis Clin North Am; 2001 Dec; 15(4):1227-61. PubMed ID: 11780273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence.
    Delarze E; Sanglard D
    Drug Resist Updat; 2015 Nov; 23():12-19. PubMed ID: 26690338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.
    Espinel-Ingroff A; Warnock DW; Vazquez JA; Arthington-Skaggs BA
    Med Mycol; 2000; 38 Suppl 1():293-304. PubMed ID: 11204157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
    Sanglard D
    Enferm Infecc Microbiol Clin; 2002 Nov; 20(9):462-9; quiz 470, 479. PubMed ID: 12425880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi].
    Mellado E; Cuenca-Estrella M; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):523-29; quiz 530, 539. PubMed ID: 12433354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging moulds: epidemiological trends and antifungal resistance.
    Miceli MH; Lee SA
    Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.
    Cuenca-Estrella M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():54-9. PubMed ID: 24372680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
    Castanheira M; Messer SA; Rhomberg PR; Pfaller MA
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):200-4. PubMed ID: 27061369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of antifungal resistance and its impact on clinical practice.
    Alcazar-Fuoli L; Mellado E
    Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds.
    Espinel-Ingroff A; Turnidge J
    Rev Iberoam Micol; 2016; 33(2):63-75. PubMed ID: 27296911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of in vitro antifungal susceptibility testing.
    Espinel-Ingroff A
    Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of resistance to antifungal agents].
    Makimura K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():466-70. PubMed ID: 17455664
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.
    Sun HY; Singh N
    Int J Antimicrob Agents; 2010 Mar; 35(3):211-8. PubMed ID: 20036518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.